Home › Companies › Ocular Therapeutix, Inc. › 2025-2026

Ocular Therapeutix, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Ocular Therapeutix, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 02 October 2026.

10Reported items
230Asset managers
1,684Fund votes
2026-06-10Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Ocular Therapeutix, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ocular Therapeutix, Inc.

These tallies are Ocular Therapeutix, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Ocular Therapeutix, Inc. — official shareholder meeting results, meeting held 2026-06-10
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Pravin U. Dugel, M.D.	142,371,228	--	--	14,705,114	32,446,509	Majority: yes
Elect Director: Merilee Raines	136,531,519	--	--	20,544,823	32,446,509	Majority: yes
(2) The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the 2026 Proxy Statement.	116,101,559	40,115,637	859,146	--	32,446,509	Majority: yes
(3) The Company's stockholders approved, on a non-binding, advisory basis, "One Year" for the frequency of future advisory votes to approve the compensation of the Company's named executive officers.	150,723,228	5,688,862	664,252	--	32,446,509	Majority: yes
(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.	187,152,838	2,113,944	256,069	--	--	Majority: yes

Source: Ocular Therapeutix, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.

How asset managers voted at the Ocular Therapeutix, Inc. 2025-2026 meeting

Each item below shows how the 230 asset managers that disclosed a Ocular Therapeutix, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ocular Therapeutix, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve an advisory vote on named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-10.

Combines 3 wordings of this item as funds reported it.

77% fund support · no official result

FOR 77%AGAINST 23%

The 220 asset managers below cast 77% of the shares they voted on this item FOR (127,248,151 for, 37,450,652 against).

FOR: 127,248,151 (77.2%)AGAINST: 37,450,652 (22.7%)ABSTAIN: 102,499 (0.1%)

Largest asset managers voting on “To approve an advisory vote on named executive officer compensation.” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	55,372,239	108,518	0	For
Deep Track Capital, LP	14,002,481	0	0	For
BlackRock	15,158	12,917,030	0	Against
T. Rowe Price	11,861,734	0	0	For
Vanguard	11,676,720	31,473	2	For
Venrock Adviser, LLC	10,346,926	0	0	For
Point72	0	5,455,956	0	Against
AllianceBernstein	4,971,156	0	0	For
Avoro Capital Advisors LLC	4,681,115	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	4,538,394	0	0	For
Logos Global Management LP	0	3,483,288	0	Against
Charles Schwab	0	2,946,840	0	Against
DELTEC ASSET MANAGEMENT LLC	2,284,868	0	0	For
State Street	6,251	2,098,056	0	Against
Boxer Capital Management, LLC	1,150,000	0	0	For
Candriam S.C.A.	0	949,216	0	Against
Northern Trust	0	910,943	0	Against
AB DISCOVERY GROWTH FUND, INC.	894,793	0	0	For
Empire Life Investments Inc.	838,830	0	0	For
Equitable	490,571	233,576	0	For
Allspring	0	607,432	0	Against
ACUTA CAPITAL PARTNERS, LLC	593,976	0	0	For
Aberdeen	0	558,380	0	Against
Dimensional	0	536,445	0	Against
MELLON INVESTMENTS Corp	0	478,558	0	Against

Showing the 25 largest of 220 asset managers. See all 220 in the interactive database.

2. To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-06-10.

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 150,723,228AGAINST: 5,688,862

Ocular Therapeutix, Inc.’s own tally for this item (“(3) The Company's stockholders approved, on a non-binding, advisory basis, "One Year" for the frequency of future advisory votes to approve the compensation of the Company's named executive officers.”): 150,723,228 for, 5,688,862 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,896,915 outstanding shares: 69% for, 3% against (71% of the company cast a for/against vote).

The 220 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

ONE YEAR 71%1 YEAR 25%

FOR: 0.9%AGAINST: 0.0%ABSTAIN: 0.1%ONE YEAR: 70.9%1 YEAR: 25.5%1-YEAR: 2.3%THREE YEARS: 0.3%3 YEARS: 0.0%1.0: 0.0%2.0: 0.0%3.0: 0.0%

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executiv” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Vote
Fidelity	0	One Year
Deep Track Capital, LP	0	1 Year
BlackRock	0	1 Year
T. Rowe Price	0	One Year
Vanguard	0	One Year
Venrock Adviser, LLC	0	One Year
Point72	0	One Year
AllianceBernstein	0	One Year
Avoro Capital Advisors LLC	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Logos Global Management LP	0	1-Year
Charles Schwab	0	1 Year
DELTEC ASSET MANAGEMENT LLC	0	1 Year
State Street	0	One Year
Boxer Capital Management, LLC	0	1 Year
Candriam S.C.A.	0	One Year
Northern Trust	0	1 Year
AB DISCOVERY GROWTH FUND, INC.	0	One Year
Empire Life Investments Inc.	884,297	For
Equitable	0	One Year
Allspring	0	One Year
ACUTA CAPITAL PARTNERS, LLC	0	1 Year
Aberdeen	0	One Year
Dimensional	0	Three Years
MELLON INVESTMENTS Corp	0	One Year

Showing the 25 largest of 220 asset managers. See all 220 in the interactive database.

3. To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Merilee Raines

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-10.

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%

FOR: 136,531,519WITHHELD: 20,544,823

Ocular Therapeutix, Inc.’s own tally for this item (“Elect Director: Merilee Raines”): 136,531,519 for, 20,544,823 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,896,915 outstanding shares: 62% for, 9% withheld (72% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (49,212,460 for, 0 against).

FOR 92%8%

FOR: 49,212,460 (91.6%)ABSTAIN: 4,535,171 (8.4%)

Largest asset managers voting on “To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	23,195,749	23,200	For
Vanguard	10,200,208	45,041	For
BlackRock	6,832,742	0	For
T. Rowe Price	4,840,331	0	For
Charles Schwab	1,463,250	0	For
AllianceBernstein	0	1,165,227	Abstain
AB DISCOVERY GROWTH FUND, INC.	0	894,793	Abstain
Equitable	255,976	468,171	Abstain
Dimensional	0	401,459	Abstain
TIAA	384,622	0	For
Brighthouse	177,700	155,373	For
Principal	0	326,514	Abstain
QUANTITATIVE MASTER SERIES LLC	306,197	0	For
Allspring	0	303,716	Abstain
OPTIMUM FUND TRUST	234,547	0	For
JPMorgan	204,749	0	For
Lincoln Financial	153,778	0	For
Empower	119,028	0	For
Erste Asset Management GmbH	0	110,000	Abstain
Transamerica	106,100	0	For
WESMARK FUNDS	0	103,000	Abstain
AIG/SunAmerica	0	99,175	Abstain
1290 Funds	0	90,230	Abstain
Simplify Exchange Traded Funds	90,000	0	For
Global X	89,038	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

4. To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Pravin U. Dugel, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-10.

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 142,371,228WITHHELD: 14,705,114

Ocular Therapeutix, Inc.’s own tally for this item (“Elect Director: Pravin U. Dugel, M.D.”): 142,371,228 for, 14,705,114 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,896,915 outstanding shares: 65% for, 7% withheld (72% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (52,099,529 for, 0 against).

FOR 97%

FOR: 52,099,529 (96.9%)ABSTAIN: 1,648,102 (3.1%)

Largest asset managers voting on “To elect two Class III directors, each to serve until the 2029 Annual Meeting of Stockholders and until his or” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	23,195,749	23,200	For
Vanguard	10,223,914	21,335	For
BlackRock	6,832,742	0	For
T. Rowe Price	4,840,331	0	For
Charles Schwab	1,463,250	0	For
AllianceBernstein	1,165,227	0	For
AB DISCOVERY GROWTH FUND, INC.	894,793	0	For
Equitable	724,147	0	For
Dimensional	0	401,459	Abstain
TIAA	384,622	0	For
Brighthouse	177,700	155,373	For
Principal	313,880	12,634	For
QUANTITATIVE MASTER SERIES LLC	306,197	0	For
Allspring	0	303,716	Abstain
OPTIMUM FUND TRUST	234,547	0	For
JPMorgan	204,749	0	For
Lincoln Financial	153,778	0	For
Empower	119,028	0	For
Erste Asset Management GmbH	0	110,000	Abstain
Transamerica	106,100	0	For
WESMARK FUNDS	0	103,000	Abstain
AIG/SunAmerica	0	99,175	Abstain
1290 Funds	0	90,230	Abstain
Simplify Exchange Traded Funds	90,000	0	For
Global X	89,038	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

5. To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-10.

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 187,152,838AGAINST: 2,113,944

Ocular Therapeutix, Inc.’s own tally for this item (“(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 187,152,838 for, 2,113,944 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 218,896,915 outstanding shares: 85% for, 1.0% against (86% of the company cast a for/against vote).

The 58 asset managers below cast 99.9% of the shares they voted on this item FOR (53,653,940 for, 9 against).

FOR 99.8%

FOR: 53,653,940 (99.8%)AGAINST: 9 (0.0%)ABSTAIN: 93,682 (0.2%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public ” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	23,218,949	0	0	For
Vanguard	10,245,246	3	0	For
BlackRock	6,832,742	0	0	For
T. Rowe Price	4,840,331	0	0	For
Charles Schwab	1,463,250	0	0	For
AllianceBernstein	1,165,227	0	0	For
AB DISCOVERY GROWTH FUND, INC.	894,793	0	0	For
Equitable	724,147	0	0	For
Dimensional	401,459	0	0	For
TIAA	384,622	0	0	For
Brighthouse	239,391	0	93,682	For
Principal	326,514	0	0	For
QUANTITATIVE MASTER SERIES LLC	306,197	0	0	For
Allspring	303,716	0	0	For
OPTIMUM FUND TRUST	234,547	0	0	For
JPMorgan	204,749	0	0	For
Lincoln Financial	153,778	0	0	For
Empower	119,028	0	0	For
Erste Asset Management GmbH	110,000	0	0	For
Transamerica	106,100	0	0	For
WESMARK FUNDS	103,000	0	0	For
AIG/SunAmerica	99,175	0	0	For
1290 Funds	90,230	0	0	For
Simplify Exchange Traded Funds	90,000	0	0	For
Global X	89,038	0	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

6. TO APPROVE AN AMENDMENT TO THE OCULAR THERAPEUTIX, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE THEREUNDER BY 10,000,000 SHARES.

COMPENSATION

Meeting held 2026-06-10.

99.9% fund support · no official result

FOR 99.7%

The 58 asset managers below cast 99.9% of the shares they voted on this item FOR (53,527,397 for, 17,069 against).

FOR: 53,527,397 (99.8%)AGAINST: 17,069 (0.0%)ABSTAIN: 93,684 (0.2%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE OCULAR THERAPEUTIX, INC. 2021 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	23,218,949	0	0	For
Vanguard	10,229,296	15,950	2	For
BlackRock	6,832,742	0	0	For
T. Rowe Price	4,840,331	0	0	For
Charles Schwab	1,463,250	0	0	For
AllianceBernstein	1,165,227	0	0	For
AB DISCOVERY GROWTH FUND, INC.	894,793	0	0	For
Equitable	724,147	0	0	For
Dimensional	401,459	0	0	For
TIAA	384,622	0	0	For
Brighthouse	239,391	0	93,682	For
Principal	326,514	0	0	For
QUANTITATIVE MASTER SERIES LLC	306,197	0	0	For
Allspring	303,716	0	0	For
OPTIMUM FUND TRUST	234,547	0	0	For
JPMorgan	204,749	0	0	For
Lincoln Financial	153,778	0	0	For
Empower	119,028	0	0	For
Transamerica	106,100	0	0	For
WESMARK FUNDS	103,000	0	0	For
AIG/SunAmerica	99,175	0	0	For
1290 Funds	90,230	0	0	For
Simplify Exchange Traded Funds	90,000	0	0	For
Global X	89,038	0	0	For
Northern Trust	86,877	0	0	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-10.

0% fund support · no official result

AGAINST 100%

The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 249,394 against).

AGAINST: 249,394 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	Against	Vote
Erste Asset Management GmbH	110,000	Against
ALGERT GLOBAL LLC	70,314	Against
CSM Advisors, LLC	69,080	Against

8. To approve an advisory vote on named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2026-04-13; no official results on file for that date.

0.1% fund support · no official result

AGAINST 99.9%

The 2 asset managers below cast 0.1% of the shares they voted on this item FOR (1 for, 187,557 against).

FOR: 1 (0.0%)AGAINST: 187,557 (100.0%)

Largest asset managers voting on “To approve an advisory vote on named executive officer compensation.” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
SCHRODER INVESTMENT MANAGEMENT GROUP	0	187,557	0	0	Against
Robertson Stephens Wealth Management, LLC	1	0	0	0	For

9. To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2026-04-13; no official results on file for that date.

— fund support · no official result

1 YEAR 99.9%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1 YEAR: 187,557 (100.0%)1YEAR: 1 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executiv” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
SCHRODER INVESTMENT MANAGEMENT GROUP	0	0	0	0	1 Year
Robertson Stephens Wealth Management, LLC	0	0	0	0	1Year

10. To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2026-06-10.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 56 against).

AGAINST: 56 (100.0%)

Largest asset managers voting on “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” at Ocular Therapeutix, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Modern Wealth Management, LLC	0	28	0	0	Against
Tandem Financial, LLC	0	28	0	0	Against

Largest Ocular Therapeutix, Inc. shareholders voting in 2025-2026

Ranked by the number of Ocular Therapeutix, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 218,896,915 shares outstanding at the time of that meeting.

Top Ocular Therapeutix, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	25.35%
2	Deep Track Capital, LP	6.40%
3	BlackRock	5.91%
4	T. Rowe Price	5.42%
5	Vanguard	5.35%
6	Venrock Adviser, LLC	4.73%
7	Point72	2.49%
8	AllianceBernstein	2.27%
9	Avoro Capital Advisors LLC	2.14%
10	GEODE CAPITAL MANAGEMENT, LLC	2.07%

Reported Ocular Therapeutix, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Ocular Therapeutix, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.92%	13F
Deep Track Capital, LP	9.53%	13G
BlackRock	7.37%	13F
Vanguard Group	5.29%	13F
T. Rowe Price	2.69%	13F
Point72	2.53%	13F
State Street	2.15%	13F
Geode Capital	2.07%	13F
Two Sigma	0.84%	13F
Invesco	0.70%	13F

Percentages above are of 218,896,915 shares outstanding, as reported by Ocular Therapeutix, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ocular Therapeutix, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Ocular Therapeutix, Inc.'s shareholder meeting held 2026-06-10, in the 2025-2026 proxy season, 230 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,684 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Ocular Therapeutix, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve an advisory vote on named executive officer compensation. — the reporting funds cast 77% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Ocular Therapeutix, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).